Billionaire investors such as Peter Thiel and Christian Angermayer are believers in the benefits of using psychedelics derived from magic mushrooms...

Eli Lilly (NYSE:LLY) has joined the Illumina Billion Cell Atlas as a founding member, forming an alliance focused on mapping human disease biology using large-scale genomic data and AI-driven drug discovery. The collaboration aims to build a detailed reference of cellular and genetic information across diseases, supporting the discovery of new drug targets. Eli Lilly enters this alliance with strong recent stock performance, with the share price at $1,146.9 and the stock up 51.5% over the...

President Donald Trump recently praised Eli Lily at a public event and called it “a great company” and highlighted its planned $3.5 billion investment for a manufacturing plant in Pennsylvania. However, Claude AI begs to differ from Trump. The AI agent recently sold its entire stake in Eli Lilly and Company (NYSE:LLY). Claude AI said […]

In the latest trading session, Eli Lilly (LLY) closed at $1, marking a -2.73% move from the previous day.

Gene-editing biotech targets up to $242.7 million valuation, with initial ASCVD trial data expected in 2027.

Healthcare stocks declined late Monday afternoon, with the NYSE Healthcare Index shedding 1.1% and t

The healthcare giant's pharma division is booming, but analysts on its latest call wanted to know if that's enough to cover for a sudden slowdown in MedTech.

Investors have flocked to Eli Lilly for exposure to the high-growth weight loss drug market.

Management lifted its profit outlook, and investors have more than quadrupled that bet. The question now is what they're really paying for.

Novo Nordisk wins EU approval for the first GLP-1 obesity tablet, expanding Wegovy's reach, but tougher competition keeps the broader investment outlook in focus.

Lilly (LLY) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

JNJ raised its 2026 outlook after strong Q2 results, but can new medicines and pipeline strength outweigh patent losses and MedTech challenges?

H.C. Wainwright and Berenberg became the latest firms to downgrade the stock following Eli Lilly's acquisition agreement.

(Bloomberg) -- The peptide boom has all the markings of a mainstream wellness craze: podcast evangelists, celebrity converts and a billion-dollar market promising shortcuts to weight loss, muscle gain and a longer life. One major hurdle: actually buying them.Most Read from BloombergUS Strikes Iran in Escalating Campaign After Troops KilledThousands of Trucks Haul Iraq’s Oil Through Syria in Sign of Hormuz LegacyUS Strikes Iran to ‘Punish’ It for Attack That Killed 2 TroopsTrump Silent So Far on

ARKG sold 1.12 million ATAI shares last week but still held 3.19 million shares as of Friday.

Investors rotated into biotech, cybersecurity and insurance stocks with stronger growth prospects and earnings strength.

Maybe you should, too.

All three pharma giants have left the S&P 500 in the dust, but surging returns and strong fundamentals tell very different stories about where each stock goes from here.

Eli Lilly stock has delivered a 406.3% return over the past five years, yet its latest valuation checks point to an unusual tension as the Discounted Cash Flow (DCF) intrinsic value suggests the shares trade at a discount while the broader scorecard still leans expensive. A roughly 5x gain over five years can signal that a lot of optimism is already reflected in Eli Lilly’s share price, putting more focus on what investors are paying for that growth story today. Expectations tied to obesity,...

Viking's latest program seeks to push the envelope in weight loss efficacy.

There's a good reason why investors are focused on Eli Lilly's GLP-1 business, but there's more going on at the company.

The drugmaker looks expensive today, but the real story is what you are actually paying for the earnings of tomorrow.

Find insight on Eli Lilly, Intuitive Surgical, European pharma stocks and more in the latest Market Talks covering the Health Care sector.

Sector leader Eli Lilly is in a buy zone above a pivot at 1,133.95 ahead of second-quarter results, due on Aug. 5.

Eli Lilly's (LLY) long-term GLP-1 franchise is unlikely to face significant pressure from generic GL

LLY agrees to acquire AtaiBeckley for $2.8B upfront to expand its neuroscience pipeline with psychedelic therapies for mental health disorders.

Big pharma is making a big bet that a DMT nasal spray could succeed where daily Prozac pills fall short.

AtaiBeckley Inc. (NASDAQ:ATAI, XETRA:9VC)'s acquisition by Eli Lilly for up to $3.8 billion reinforces growing interest from large pharmaceutical companies in psychedelic-based therapies, according to analysts at Jefferies, who believe that the deal reflects increasing momentum driven by...

Companies In The Article Are:ASTS,ATAI,LLY,USB,CFG

The weight-loss boom has created one of the market's biggest opportunities — and some of its most punishing failures.

Eli Lilly and Company has agreed to acquire AtaiBeckley (NasdaqGM:ATAI) in a cash and contingent value rights deal valued at up to $3.8b, putting fresh focus on the stock’s risk and return trade off. See our latest analysis for AtaiBeckley. AtaiBeckley’s share price has reacted sharply to the Eli Lilly bid, with a 33.4% 1 day share price return on the announcement and an 84.75% year to date share price return. The 1 year total shareholder return of 156.27% contrasts with a 5 year total...

Eli Lilly's first venture into psychedelic medicine, a takeover of AtaiBeckley worth up to $3.8 billion, is above all a vindication of two decades of British research once dismissed as fringe science. The prize at the centre of the deal is BPL-003, a nasal spray formulation of the psychedelic...

Despite an FDA crackdown and numerous pharma lawsuits, nearly 1 in 5 patients are taking cheaper weight-loss alternatives despite the risks.

The deal gives Eli Lilly access to a ⁠psychedelic-based nasal spray that studies show curbs treatment-resistant depression in a single dose.

Apple, AtaiBeckley and UnitedHealth Group jumped to yearly highs as positive company catalysts, Wall Street upgrades, and strong earnings pushed shares higher.

AtaiBeckley climbed to a new four-year high on Thursday, as investors bought into its shares following news that Eli Lilly agreed to acquire the company for up to $3.8 billion. In intra-day trading, the stock surged to a record high of $7.22 before trimming gains to end the session just up by 33.40 percent at […]

The psychedelic drugmaker is being acquired.